Monoclonal antibody | |
---|---|
Type | ? |
Target | CD19 and Fc gamma receptor IIb |
Clinical data | |
Other names | AMG 729 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." [1] [2]
Monoclonal antibody | |
---|---|
Type | ? |
Target | CD19 and Fc gamma receptor IIb |
Clinical data | |
Other names | AMG 729 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." [1] [2]